Data / Research funding / Digestive Diseases - (Gallbladder)
Digestive Diseases - (Gallbladder): 57 NIH awards ($50.7M) to 40 organizations
57 NIH awards ($50.7M) in the NIH spending category Digestive Diseases - (Gallbladder), to 40 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
57 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Mechanisms of the Development and Maintenance of Salmonella Gallbladder Carriage | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,105,141 | June 1, 2015 | April 30, 2027 | GUNN, JOHN S | reporter.nih.gov |
| Dissecting the pathogenesis and outcomes of PSC using multi-omics by studying the exposome and genome | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $3,027,125 | September 1, 2018 | July 31, 2025 | LAZARIDIS, KONSTANTINOS N | reporter.nih.gov |
| Searching the blood metabolome to identify risk biomarkers for biliary tract cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,714,799 | May 1, 2022 | April 30, 2027 | SHU, XIAO-OU | reporter.nih.gov |
| Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR) | NIH | National Cancer Institute | 2021 to 2024 | $2,581,284 | September 10, 2020 | August 31, 2025 | JARNAGIN, WILLIAM ROBERT | reporter.nih.gov |
| Surgical Simulator for Improving Skill Proficiency and Resilience | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,176,575 | September 1, 2021 | May 31, 2026 | ENQUOBAHRIE, ANDINET ASMAMAW | reporter.nih.gov |
| Mechanisms of gallbladder smooth muscle dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,161,620 | July 18, 2022 | May 31, 2027 | LAVOIE, BRIGITTE | reporter.nih.gov |
| International Consortium for the Genetics of Biliary Tract Cancers Cholangiocarcinoma Genome Wide Association Study | NIH | National Cancer Institute | 2023 to 2025 | $2,005,621 | April 10, 2023 | March 31, 2028 | ROBERTS, LEWIS R | reporter.nih.gov |
| TOPIC 388: IN VITRO DIAGNOSTIC FOR THE LIVER FLUKES OPISTHORCHIS VIVERRINI AND CLONORCHIS SINENSI | NIH | National Cancer Institute | 2021 | $1,999,961 | September 16, 2021 | September 15, 2023 | LEVIN, ANDREW | reporter.nih.gov |
| Functions of mutant IDH in cholangiocarcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,927,919 | September 20, 2023 | August 31, 2028 | EL-BARDEESY, NABEEL | reporter.nih.gov |
| Primary cilia loss in bile duct cells- the interplay with the autophagy machinery | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,615,111 | February 1, 2023 | January 31, 2027 | GRADILONE, SERGIO A | reporter.nih.gov |
| Identifying therapeutic options for intrahepatic cholangiocarcinoma | NIH | National Cancer Institute | 2021 to 2025 | $1,588,482 | April 15, 2021 | March 31, 2027 | KO, SUNGJIN | reporter.nih.gov |
| Exploring novel SRC-regulated pathways in IDH mutant intrahepatic cholangiocarcinoma | NIH | National Cancer Institute | 2022 to 2025 | $1,574,167 | April 1, 2021 | March 31, 2027 | KUGEL, SITA | reporter.nih.gov |
| Koli: A non-surgical solution for gallstone disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $1,497,166 | September 1, 2023 | August 31, 2025 | CHENG, CHRISTOPHER | reporter.nih.gov |
| GPR30 and hepatic cholesterol metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,406,568 | July 10, 2020 | June 30, 2024 | PESSIN, JEFFREY E. | reporter.nih.gov |
| Multispectral imaging of bile duct epithelial morphology for early detection of malignancy | NIH | National Cancer Institute | 2024 to 2025 | $1,398,638 | July 1, 2024 | June 30, 2029 | PERELMAN, LEV T | reporter.nih.gov |
| Anti-cancer vaccine targeting the host-parasite interface during fluke infection | NIH | National Cancer Institute | 2021 to 2025 | $1,391,200 | September 21, 2012 | August 31, 2029 | BRINDLEY, PAUL J | reporter.nih.gov |
| Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma | NIH | National Cancer Institute | 2021 to 2022 | $1,230,719 | June 19, 2018 | May 31, 2024 | SCHWABE, ROBERT F. | reporter.nih.gov |
| Dissecting a novel tumor-promoting axis in cholangiocarcinoma | NIH | National Cancer Institute | 2024 to 2025 | $1,224,644 | August 13, 2024 | July 31, 2029 | SIA, DANIELA | reporter.nih.gov |
| Radiation and dendritic cell combination to improve immunotherapy response in intrahepatic cholangiocarcinoma | NIH | National Cancer Institute | 2024 to 2025 | $1,221,780 | September 1, 2024 | August 31, 2029 | PARK, SEAN S | reporter.nih.gov |
| A new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy | NIH | National Cancer Institute | 2023 to 2024 | $1,099,610 | September 19, 2023 | August 31, 2028 | KARIN, MICHAEL | reporter.nih.gov |
| Epigenetic Mechanisms of Biliary Epithelial Neoplasia | NIH | National Cancer Institute | 2021 to 2025 | $979,804 | July 1, 2018 | December 31, 2029 | WU, TONG | reporter.nih.gov |
| The Pro-Tumor Immunologic Niche of the Liver | NIH | National Cancer Institute | 2021 to 2023 | $728,694 | September 1, 2019 | August 31, 2024 | ILYAS, SUMERA I. | reporter.nih.gov |
| A new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy | NIH | National Cancer Institute | 2025 | $695,955 | September 19, 2023 | August 31, 2028 | KARIN, MICHAEL | reporter.nih.gov |
| Harnessing mutant IDH1 as a therapeutic target in liver cancer and other solid malignancies | NIH | National Cancer Institute | 2025 | $693,781 | April 14, 2025 | March 31, 2030 | EL-BARDEESY, NABEEL | reporter.nih.gov |
| FGFR4 intracellular domain promotes tumor progression in cholangiocarcinoma | NIH | National Cancer Institute | 2021 to 2022 | $689,636 | January 1, 2018 | December 31, 2023 | MOTT, JUSTIN L. | reporter.nih.gov |
| The Natural History of Overall Mortality with Diagnosed Symptomatic Gallstone Disease in the United States: A Sequential Mixed-methods Study Evaluating Emergency, Non-emergency, and No Cholecystectomy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $687,537 | July 15, 2023 | May 31, 2027 | PECK, GREGORY LANCE | reporter.nih.gov |
| Glycan Biomarkers for Cholangiocarcinoma | NIH | National Cancer Institute | 2025 | $671,384 | December 5, 2024 | November 30, 2029 | MEHTA, ANAND S. | reporter.nih.gov |
| Simulation based surgical training for high risk low resourced procedures using a novel simulator with smart mentoring | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 | $611,305 | September 23, 2022 | September 22, 2024 | NELSON, CARL A | reporter.nih.gov |
| Epidemiology and Genomics of Multidrug resistant Salmonella Typhi infections in Kenya: The role of carriage in an endemic setting | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $528,391 | February 15, 2013 | March 31, 2025 | KARIUKI, SAMUEL M | reporter.nih.gov |
| Deciphering the Molecular Mechanisms Underlying Cholangiocarcinoma Development | NIH | National Cancer Institute | 2025 | $518,219 | April 4, 2025 | March 31, 2030 | KO, SUNGJIN | reporter.nih.gov |
| The Role Wnt Signaling in Biliary Homeostasis and Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $500,580 | July 1, 2021 | August 1, 2023 | GUPTA, VIKAS | reporter.nih.gov |
| Molecular regulation of cholestasis in cholangiocytes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $478,862 | May 15, 2018 | April 30, 2023 | NATHANSON, MICHAEL H | reporter.nih.gov |
| SUPPORT SERVICES FOR INTEGRATIVE EPIDEMIOLOGICAL STUDIES | NIH | National Cancer Institute | 2022 to 2023 | $426,000 | September 22, 2023 | March 21, 2024 | GLASSHOFER, SARA | reporter.nih.gov |
| Salmonella chronic infection: Biofilm matrix factors and innate immune tolerance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $423,500 | December 17, 2020 | November 30, 2023 | GUNN, JOHN S | reporter.nih.gov |
| Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma | NIH | National Cancer Institute | 2021 | $412,434 | July 3, 2018 | June 30, 2023 | LESINSKI, GREGORY B. | reporter.nih.gov |
| A collaborative cross mouse model of Salmonella Typhi Chronic Carriage | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $402,985 | August 1, 2025 | July 31, 2027 | GUNN, JOHN S | reporter.nih.gov |
| Exploring novel SRC-regulated pathways in IDH mutant intrahepatic cholangiocarcinoma | NIH | National Cancer Institute | 2021 | $402,600 | April 1, 2021 | March 31, 2022 | KUGEL, SITA | reporter.nih.gov |
| Contrast-Enhanced Ultrasound for Diagnosis and Therapy of Cholangiocarcinoma | NIH | National Cancer Institute | 2022 to 2023 | $397,469 | December 3, 2021 | May 31, 2025 | EISENBREY, JOHN | reporter.nih.gov |
| Apolipoprotein A5 and Gallstone Formation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $375,750 | July 20, 2018 | April 30, 2023 | WANG, DAVID Q | reporter.nih.gov |
| Mechanism-based combination therapy for cholangiocarcinoma | NIH | National Cancer Institute | 2023 to 2024 | $373,152 | April 5, 2023 | March 31, 2026 | YOON, KARINA J | reporter.nih.gov |
| SBIR CONCEPT AWARD-NANOSPONGE LINKED DCLK1 INHIBITORS FOR THE TARGETED TREATMENT OF CHOLANGIOCARCINOMA | NIH | National Cancer Institute | 2023 | $353,412 | February 28, 2023 | February 27, 2024 | SIELECKI, THAIS | reporter.nih.gov |
| Modulation of the biliary immune niche by the microbiome - Administrative supplement | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $333,000 | June 20, 2023 | May 31, 2025 | O'LEARY, CLAIRE E | reporter.nih.gov |
| MKK4 Regulation of Liver Regeneration after Resection of Colorectal Metastasis or Hilar Cholangiocarcinoma | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $322,800 | August 13, 2025 | June 30, 2028 | NYBERG, SCOTT LYLE | reporter.nih.gov |
| Metabolomics of symptomatic gallstone disease in COMETS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $252,000 | March 1, 2021 | February 28, 2023 | JOSHI, AMIT DOLAR | reporter.nih.gov |
| Regulation and role of Salmonella curli during chronic infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $231,000 | July 17, 2020 | June 30, 2023 | GUNN, JOHN S | reporter.nih.gov |
| Deciphering the Immune Evasion Mechanisms in Mutant IDH1 Cancer | NIH | National Cancer Institute | 2025 | $196,029 | April 1, 2025 | March 31, 2028 | WU, MENG-JU | reporter.nih.gov |
| Exploiting metabolic reprogramming to target IDH1 mutated cholangiocarcinoma | NIH | National Cancer Institute | 2021 | $178,200 | March 1, 2020 | February 28, 2022 | SHI, LEI | reporter.nih.gov |
| Targeting Ferroptosis in Cholangiocarcinoma with siRNA-based Nanovesicles | NIH | National Cancer Institute | 2025 | $161,400 | August 1, 2025 | July 31, 2027 | POVERO, DAVIDE | reporter.nih.gov |
| Evaluation of voltage-gated calcium ion channels as a therapeutic target in intrahepatic cholangiocarcinoma | NIH | National Cancer Institute | 2022 to 2023 | $155,916 | July 1, 2022 | June 11, 2024 | LIU, ANNIE | reporter.nih.gov |
| Adaptive immunity in primary sclerosing cholangitis patients at risk for colorectal cancer | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $102,788 | July 1, 2019 | June 30, 2023 | SHAW, DUSTIN | reporter.nih.gov |
| Identifying drivers of periductal fibrosis in primary sclerosing cholangitis using single-cell analysis of patient biospecimens | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $102,752 | July 11, 2024 | July 10, 2028 | HERB, JAKE | reporter.nih.gov |
| Noninvasive assessment of IDH mutation status in intrahepatic cholangiocarcinoma | NIH | National Cancer Institute | 2024 to 2025 | $98,512 | May 1, 2024 | April 30, 2027 | ZAVRIYEV, ALEXANDER | reporter.nih.gov |
| Risk Prediction of Symptomatic Gallbladder Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $79,596 | September 1, 2016 | January 31, 2023 | JOSHI, AMIT DOLAR | reporter.nih.gov |
| Investigating the role of stromal YAP activation in intrahepatic cholangiocarcinoma | NIH | National Cancer Institute | 2021 to 2022 | $76,306 | July 1, 2020 | July 29, 2022 | RUSSELL, JACQUELYN OLIVIA | reporter.nih.gov |
| Albumin-binding nanocomplexes for delivery of combination siRNA therapeutics to KRAS-driven cholangiocarcinoma | NIH | National Cancer Institute | 2022 | $76,246 | July 1, 2022 | June 30, 2023 | LO, JUSTIN HAN-JE | reporter.nih.gov |
| Multi-ancestry genome-wide association studies of biliary tract cancer | NIH | National Cancer Institute | 2025 | $49,538 | July 14, 2025 | July 13, 2028 | GUNCHICK, VALERIE | reporter.nih.gov |
| The Cholangiocarcinoma Conference: Molecular Drivers, Microenvironment, and Precision Medicine | NIH | National Cancer Institute | 2023 | $14,000 | August 1, 2023 | July 31, 2024 | SIRICA, ALPHONSE E | reporter.nih.gov |
Organizations
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 26 | $11,083,681 | 0 | $0 |
| 2024 | 22 | $9,610,046 | 0 | $0 |
| 2023 | 25 | $9,466,953 | 0 | $0 |
| 2022 | 25 | $9,867,660 | 0 | $0 |
| 2021 | 25 | $10,701,323 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.